Ferdy J. Lejeune

Immunology and Microbiology · Life Sciences

51h-index10.1kcitations179works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(58), Cutaneous Melanoma Detection and Management(39), CAR-T cell therapy research(30), Melanoma and MAPK Pathways(25), Cancer Immunotherapy and Biomarkers(19)

Publications179 total

Supplementary Table 1 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
2025Open Access
Supplementary Table 5 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
2025Open Access
Supplementary Table 4 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
2025Open Access
Supplementary Table 2 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
2025Open Access
Supplementary Table 3 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
2025Open Access
Supplementary Table 1 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
2023Open Access
Supplementary Table 2 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
2023Open Access
Supplementary Table 3 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
2023Open Access
Supplementary Table 2 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
2023Open Access
Supplementary Table 1 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
2023Open Access
Supplementary Table 3 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
2023Open Access
Supplementary Table 5 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
2023Open Access
Data from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
2023Open Access
Supplementary Table 4 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
2023Open Access
Supplementary Table 4 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
2023Open Access
Supplementary Table 5 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
2023Open Access
Data from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
2023· 1 citedOpen Access
Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
Clinical Cancer Research·2022· 23 citedOpen Access
Thirty years of therapeutic innovation in melanoma research
Melanoma Research·2021
Combination of Triptorelin with Nivolumab in ICI Resistant Advanced Melanoma
Annals of Oncology·2019· 1 cited
page 1 of 9Next →

Frequent Co-authors

Danielle Líénard(24), Donata Rimoldi(16), Jean‐Charles Cerottini(16), Daniel E. Speiser(15), Pedro Romero(14), Danila Valmori(11), Mikäel J. Pittet(10), Philippe Guillaume(9), D. Liénard(8), Valérie Dutoit(7), Verena Rubio‐Godoy(5), Serge Leyvraz(5), Alexander M.M. Eggermont(5), Alfred Zippelius(5), Curzio Rüegg(4), Philippe Autier(4), Maha Ayyoub(4), Patricia Ewalenko(3), Nathalie Rufer(3), Vincenzo Cerundolo(3)